The integration of GLP‐1 RAs and tirzepatide into the therapeutic strategy for patients with HF and obesity requires careful patient selection based on clinical characteristics, HF stage and phenotype (Figure 1). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.